Summary of Precigen Conference Call Company Overview - **Company**: Precigen - **Key Product**: Papzimeos, an immunotherapy for recurrent respiratory papillomatosis (RRP) - **Leadership**: Helen Sabzevari (President and CEO), Phil Tennant (Chief Commercial Officer) Core Industry Insights - **FDA Approval**: Papzimeos received FDA approval, marking a significant milestone for Precigen as it transitions into a commercial stage entity [1] - **Market Need**: RRP has historically lacked effective treatments, with patients often undergoing multiple surgeries, leading to severe complications [10][11] - **Patient Demographics**: RRP can affect both children and adults, with severe cases requiring numerous surgeries annually [10][11] Product Details - **Mechanism of Action**: Papzimeos utilizes a unique gorilla adenovirus platform, allowing for a higher capacity of gene presentation (up to 12 KB) and the ability to administer multiple doses without immunogenicity issues [4][5] - **Clinical Efficacy**: In pivotal studies, Papzimeos demonstrated a 51% complete response rate and an 86% overall reduction in surgeries among patients [15][16] - **Safety Profile**: The treatment has shown a favorable safety profile, comparable to receiving a flu shot [61] Commercial Strategy - **Launch Metrics**: The company began dosing patients in November, with a straightforward regimen of four subcutaneous injections over 12 weeks [20][21] - **Market Focus**: Precigen identified approximately 500 hospital systems as key targets for initial commercialization, with a focus on large academic centers and community hospitals [25] - **Patient Engagement**: The company is actively working with patient advocacy groups to raise awareness and ensure patients are informed about treatment options [33][36] Future Plans - **Redosing Studies**: Ongoing studies aim to convert partial responders to complete responders through additional dosing [19][62] - **Pediatric Trials**: Plans to initiate pediatric trials by the end of 2026, expanding the treatment's applicability to younger patients [62] - **Platform Expansion**: Development of PRGN-2009, targeting HPV-related cancers, is underway, leveraging the same adenovirus platform as Papzimeos [64][65] Financial Outlook - **Revenue Projections**: The company anticipates significant revenue growth from Papzimeos, with expectations of reaching break-even by the end of 2026 [82] - **Funding Utilization**: With over $100 million in the bank, Precigen plans to allocate resources towards redosing studies, pediatric trials, and the expansion of PRGN-2009 [84] Key Challenges and Considerations - **Payer Access**: While the company has seen positive payer coverage, some restrictions exist based on prior surgical history [47][49] - **Market Education**: Continuous efforts are needed to educate healthcare providers and patients about RRP and the new treatment options available [36][37] Conclusion Precigen is positioned to make a significant impact in the treatment of RRP with Papzimeos, addressing a long-standing unmet medical need. The company's innovative approach, combined with strategic commercialization efforts and future expansion plans, suggests a promising outlook for both patient outcomes and financial performance.

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, totaled $9.7 million, an increase of $5.8 million or 149% compared to $3.8 million in 2024, primarily driven by the commencement of PAPZIMEOS product revenue [12][13] - Net product revenue for Q4 2025 was $3.4 million, with expectations for Q1 2026 revenues to exceed $18 million based on commercial activity to date [4][14] - The net loss attributable to common shareholders was $429.6 million or $1.37 per share for the year ended December 31, 2025, including non-cash items totaling $318.5 million [16][17] Business Line Data and Key Metrics Changes - The launch of PAPZIMEOS represents a significant transition from an R&D company to a product revenue-generating commercial biotech company [3] - The number of patients in the Precigen patient support hub grew from over 200 in mid-January to well over 300, indicating strong demand for PAPZIMEOS [9][10] - Payer coverage expanded from approximately 170 million lives in early January to about 215 million, covering nearly 90% of insured lives in the U.S. [10] Market Data and Key Metrics Changes - The FDA granted full approval for PAPZIMEOS with a broad label for adult RRP, which has led to strong interest from both patients and physicians [5][6] - The publication of an expert consensus paper positioned PAPZIMEOS as the first choice for adult patients with RRP, enhancing its market acceptance [11] Company Strategy and Development Direction - The company is actively advancing plans for a clinical trial of PAPZIMEOS in the pediatric RRP population, with hopes to initiate this in Q4 2026 [18] - Geographic expansion efforts are underway, including the validation of the marketing authorization application to the EMA for PAPZIMEOS [18] - The company aims to transition the management of RRP from surgical interventions to therapeutic management, reflecting a significant shift in treatment strategy [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong uptake of PAPZIMEOS and the anticipated revenue growth, indicating a robust launch trajectory [14][16] - The assignment of a permanent J-code from April 1 is expected to streamline the reimbursement process and enhance patient access to PAPZIMEOS [28][34] - Management highlighted the importance of payer coverage and institutional activation in driving patient treatment and revenue growth [25][36] Other Important Information - The company ended the year with $100.4 million in cash equivalents and investments, which is expected to fund operations through cash flow breakeven by the end of 2026 [17] - The company continues to advance the PRGN-2009 program, which targets HPV 16 and 18 associated cancers [19] Q&A Session Summary Question: Flow of patients from the hub to receiving reimbursed drug - Management indicated that there is significant conversion of patients from the hub and that the goal is to ensure the majority of patients receive treatment [24][26] Question: Patients starting to get their second dose - Management confirmed that patients are moving through their treatment regimens, including receiving second doses as needed [26][27] Question: Impact of the J-code on patient flow - The J-code is expected to simplify the workflow and billing process, increasing the speed at which patients are processed [34] Question: Clarification on $18 million revenue guidance - The $18 million guidance refers only to PAPZIMEOS product revenue, excluding other revenue sources [45] Question: Community uptake and differentiating factors - Management noted that community sites are showing significant interest and that logistics support is aiding in their adoption of PAPZIMEOS [54][55] Question: Current channel mix of U.S. payers - The payer mix is approximately 60%-65% commercial, consistent with prior expectations [57]

Financial Data and Key Metrics Changes - For the year ended December 31, 2025, total revenue was $9.7 million, a significant increase of $5.8 million or 149% compared to $3.8 million in 2024, primarily driven by the launch of Papzimeos [12][16] - Net product revenue for Q4 2025 was $3.4 million, with expectations for Q1 2026 revenues to exceed $18 million based on early commercial activity [4][13] Business Line Data and Key Metrics Changes - The launch of Papzimeos has transitioned the company from an R&D-focused entity to a revenue-generating commercial biotech company, marking a pivotal milestone [3] - The company reported strong momentum in patient uptake, with over 300 patients in the support hub by mid-January, indicating robust demand for Papzimeos [10] Market Data and Key Metrics Changes - Payer coverage for Papzimeos has expanded from approximately 170 million lives in early January to about 215 million, covering nearly 90% of insured lives in the U.S. [10] - The publication of an expert consensus paper has positioned Papzimeos as the first choice for adult patients with RRP, enhancing its market acceptance [11] Company Strategy and Development Direction - The company is actively pursuing geographic expansion, including a marketing authorization application to the EMA for Papzimeos, with positive feedback from European thought leaders [18] - Plans to initiate a clinical trial for Papzimeos in pediatric RRP patients are underway, expected to start in Q4 2026 [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong uptake of Papzimeos, with expectations for continued revenue growth and institutional activation [11][12] - The company anticipates reaching cash flow breakeven by the end of 2026, supported by projected sales from Papzimeos [17] Other Important Information - Research and development expenses decreased by 22.1% compared to 2024, while selling, general, and administrative expenses increased by 69.8% due to costs associated with Papzimeos commercial activities [14][15] - The net loss attributable to common shareholders for 2025 was $429.6 million, influenced by non-cash items related to preferred stock and warrants [16] Q&A Session Summary Question: Flow of patients from the hub to receiving reimbursed drug - Management indicated that there is significant conversion of patients from the support hub, with a goal to ensure the majority receive treatment [21][24] Question: Patients starting to get their second dose - Management confirmed that patients are progressing through their treatment regimens, with some already receiving their second dose [26][27] Question: Impact of the J-code on patient flow - The J-code is expected to streamline the billing process, enhancing the speed at which patients are processed for treatment [28][34] Question: Clarification on $18 million revenue guidance - The $18 million guidance refers solely to Papzimeos product revenue, excluding other revenue sources [44] Question: Community uptake and prescriber differentiation - Management noted that community sites are showing significant interest in prescribing Papzimeos, aided by logistical support for low-cost access [52][53]

Core Insights - Patient Capital Management, LLC increased its position in Precigen by 10.2 million shares during Q3 2025, with an estimated transaction value of $28.78 million [1] - Precigen's stock price reached $4.01 as of October 29, 2025, reflecting a 375.91% increase over the past year, significantly outperforming the S&P 500 [2] - Precigen's market capitalization stands at $1.19 billion, with a trailing twelve months (TTM) revenue of $4.34 million and a net income loss of $124.50 million [3] Company Overview - Precigen specializes in gene and cellular therapies, disease-modifying therapeutics, and proprietary platforms such as UltraVector, Sleeping Beauty, UltraCAR-T, and AdenoVerse Immunotherapy [4][5] - The company operates a business model focused on research, development, and strategic collaborations within the biotechnology and healthcare sectors [4] Strategic Positioning - Precigen has a diversified technology portfolio and strategic collaborations that enable it to address complex medical needs in oncology and regenerative medicine [5] - The company’s competitive advantage lies in its proprietary platforms and partnerships that facilitate advancements in disease-modifying therapeutics [5] Recent Developments - Precigen's stock price surged after the FDA granted full approval to its drug Papzimeos, which treats recurrent respiratory papillomatosis (RRP), a condition affecting approximately 27,000 adults in the U.S. [7][8] - The addressable population for Papzimeos may grow as new patients seek treatment options for their debilitating conditions [8] Investment Insights - Precigen represents a significant holding for Patient Capital, accounting for 3.5% of its portfolio, up from just 1% at the end of the second quarter [6] - The stock has increased by 191.5% since June 30, 2025, indicating a strong performance for investors [7]

Fund Performance - The Patient Opportunity Equity Strategy achieved a total return of 14.1% net of fees in Q3 2025, outperforming the S&P 500 Index which returned 8.1% [2] - The portfolio's outperformance was driven by selection and interaction effects, while allocation effects partially offset these gains [3] Portfolio Composition - The strategy was overweight in sectors such as Consumer Discretionary, Communication Services, Financials, Energy, Industrials, and Health Care, while underweight in Real Estate, Utilities, Materials, Consumer Staples, and Information Technology [4] - The portfolio ended the quarter with 36 holdings, with the top 10 stocks representing 51.1% of total assets, indicating a high active share of approximately 92.5% [5] Market Context - The market's upward trend in Q3 was supported by resilient consumer spending, Federal Reserve rate cuts, and ongoing AI investments [6] - Long-held positions in the portfolio broke through multi-year resistance levels, contributing to overall performance [6] Key Contributors - Precigen (PGEN) was the top contributor, benefiting from the FDA approval of Papzimeos, which is expected to launch soon [10][15] - Alphabet Inc. (GOOGL) and Alibaba Group Holdings (BABA) also significantly contributed to performance, with GOOGL gaining regulatory clarity and BABA announcing aggressive AI investment plans [8][16][17] Key Detractors - Dave & Buster's Entertainment (PLAY) was the largest detractor due to disappointing results and leadership changes, although there is optimism for future recovery under new management [18] - QXO Inc. (QXO) faced concerns over weakening construction activity but continues to execute its acquisition strategy [19] - Crocs Inc. (CROX) declined following disappointing guidance and challenges with its HEYDUDE brand [20][21] Strategic Actions - The portfolio eliminated five positions during the quarter, reallocating capital towards higher conviction names [12] - The strategy continues to capitalize on market volatility, increasing positions in Delta Air Lines (DAL) and Norwegian Cruise Line Holdings (NCLH) during market pullbacks [9]

Group 1 - Precigen, Inc. (NASDAQ: PGEN) shares have significantly increased following the FDA's full approval of its recurrent respiratory papillomatosis therapy, Papzimeos, on August 14th, marking the first-ever approval for this indication [2] Group 2 - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions on trade ideas and weekly market commentary [2]

Group 1 - Precigen Inc. (NASDAQ:PGEN) is recognized as a promising multibagger stock, particularly due to its UltraCAR-T platform which aims for faster manufacturing and improved safety profiles in CAR-T treatments [1] - The company's stock has surged over 300% year-to-date, with a notable doubling of share price since mid-August following the FDA approval of its Papzimeos therapy, the first approved treatment for adults with recurrent respiratory papillomatosis [2] - Analysts have reacted positively to the FDA approval, with JPMorgan upgrading the stock to Neutral from Underweight, and Cantor Fitzgerald and H.C. Wainwright reaffirming their Buy ratings [3] Group 2 - The FDA approval of Papzimeos is seen as favorable, covering a broad indication for approximately 27,000 U.S. adults, with projected sales of $15 million by Q4 2025 [4] - Precigen focuses on developing gene and cellular therapies, particularly in the fields of immuno-oncology, autoimmune disorders, and infectious diseases [5]

Core Viewpoint - The healthcare sector is experiencing significant stock price increases, with some stocks more than doubling in value since the end of July, indicating potential for further gains despite recent surges [1][2]. Group 1: Precigen - Precigen's shares increased by 155% from the end of July to September 5, following FDA approval for its first treatment, Papzimeos, which is aimed at recurrent respiratory papillomatosis (RRP) [4][5]. - Papzimeos is the first and only FDA-approved treatment for approximately 27,000 patients with RRP, with a notable response rate in clinical trials where 18 out of 35 patients avoided surgery for at least 12 months post-treatment [5][6]. - Analysts, including Swayampakula Ramakanth from HC Wainwright, have set a price target of $8.50 for Precigen, suggesting a potential 95% increase in the next year [6]. Group 2: Mineralys Therapeutics - Mineralys Therapeutics saw a 146% rise in stock price from the end of July to September 5, driven by a successful funding round for the development of its lead candidate, lorundrostat [7][8]. - The company raised $287.5 million through a secondary offering, which followed the suspension of an at-the-money equity offering [8]. - In a phase 3 trial, lorundrostat demonstrated a significant reduction in systolic pressure, outperforming a placebo [9]. - Following AstraZeneca's less favorable data for a competing product, Bank of America analyst Greg Harrison raised the target price for Mineralys to $43 per share, indicating a potential 24% gain [11]. - Despite the positive outlook, the company ended June with $325 million in cash, sufficient to last until 2027, raising concerns about the urgency of submitting for approval [12]. - Mineralys has a market cap of $2.7 billion, which could be affected by the timing of lorundrostat's approval compared to competitors [14]. Group 3: Market Potential - Precigen's market cap is approximately $1.3 billion, with expectations for Papzimeos potentially underestimated, as it is set to launch in a niche market without competition [15]. - Papzimeos could generate over $1 billion in annual sales at peak pricing, with a list price exceeding $200,000 per patient per year [16].

Core Insights - Inovio Pharmaceuticals' shares increased by 20.6% following FDA's acceptance of a rolling submission timeline for the biologics license application (BLA) for INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP) in adults [1][5] - The company plans to finalize the BLA submission in the coming months and seeks priority review, targeting FDA acceptance by the end of 2025 [1][2] - INO-3107 is designed to elicit a targeted T cell response against HPV-6 and HPV-11, which cause RRP, and has received breakthrough therapy and orphan drug designations in the U.S. [3][5] Company Developments - Inovio's BLA submission is supported by data from a completed phase I/II study that demonstrated the candidate's safety, tolerability, immunogenicity, and efficacy in patients with HPV-related RRP [6] - The FDA has indicated that the completed study could support a BLA filing under the accelerated approval program, negating the need for a pivotal phase III study [6] - A confirmatory study for INO-3107 will be initiated, enrolling 100 patients across the U.S. [7] Industry Context - Precigen, Inc. recently received FDA approval for Papzimeos, a treatment for RRP, which also holds breakthrough therapy and orphan drug designations [8] - Precigen's Papzimeos was approved based on data from a pivotal phase I/II study, which met primary safety and efficacy endpoints, eliminating the need for a confirmatory study [10] - Year-to-date, Inovio's shares have risen by 34.4%, significantly outperforming the industry average growth of 3.2% [4]

Core Insights - The report highlights the approval of semaglutide (Wegovy) for the treatment of metabolic dysfunction-associated steatotic liver disease (MASH) by the FDA, which is expected to enhance the market penetration of related products and diagnostic tools [7][10][15] - The report suggests that companies like Furuya Co., Ltd. will benefit from the growth opportunities in the MASH indication market due to the increasing prescription rates of semaglutide and the rising demand for diagnostic instruments [15][5] Industry Performance Review - As of August 15, 2025, the pharmaceutical and biotechnology sector's TTM-PE stands at 51.31 times, which is 110% higher than its historical low of 24.38 times [16] - The healthcare sector has shown a relative premium of 281% compared to the CSI 300 index, which is significantly above the average premium rate of 241% over the past decade [16] - The pharmaceutical and biotechnology sector experienced a 3.08% increase in the week from August 11 to August 15, 2025, ranking 10th among 27 sub-industries [20][24] Company Dynamics - Furuya Co., Ltd. is noted for its FibroScan series of liver fibrosis diagnostic instruments, which are the first globally to utilize transient elastography technology for non-invasive liver stiffness measurement [15] - The report emphasizes the strategic collaborations between Furuya and leading pharmaceutical companies to promote the clinical application and commercialization of new drugs [15] - The report identifies several companies that could be key players in the MASH treatment landscape, including innovative drug and device companies such as Furuya, Anglikon, and others [15]